Skip to content

A single-arm, single-center study on PSMA-targeted fluorescence-assisted precise radical prostatectomy for prostate cancer

A single-arm, single-center study on PSMA-targeted fluorescence-assisted precise radical prostatectomy for prostate cancer

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118060
Enrollment
Unknown
Registered
2026-02-02
Start date
2026-02-02
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

PSMA-targeted fluorescence navigation–assisted robot-assisted radical prostatectomy (Single-arm):Intravenous injection of ICG-18F-PSMA fluorescent probe at 1 µg/kg 24 hours before surgery, followed by
vital signs and potential adverse reactions will be dynamically monitored after injection. Intraoperative PSMA-targeted fluorescence image-guided navigation using the da Vinci Firefly near-infrared im

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with prostate adenocarcinoma via transrectal prostate biopsy; 2. Scheduled to undergo robot-assisted radical prostatectomy. 3. Preoperative assessment indicates suspected tumour capsular invasion.

Exclusion criteria

Exclusion criteria: 1.Biopsy pathology indicates a special histologic subtype; 2.Acute urinary tract infection not adequately controlled; 3.History of allergic reactions to PSMA imaging agents or fluorescent contrast agents; 4.Prior radiotherapy or surgery involving the lower urinary tract or pelvis; 5.Current hepatic or renal dysfunction (laboratory values >2× the upper limit of normal); 6.Major comorbidities (e.g., autoimmune disease, angina, heart failure, hematologic disorders, severe respiratory or gastrointestinal diseases), or deemed unable to tolerate surgery by multidisciplinary evaluation; 7.Any other condition considered unsuitable for participation by the investigator.

Design outcomes

Primary

MeasureTime frame
Positive surgical margin rate;Urinary continence recovery rate at 1 month postoperatively;

Secondary

MeasureTime frame
Detection rate of extraprostatic extension (EPE);Intraoperative fluorescence detection rate versus PET-MR and pathology detection rates;Time to biochemical recurrence after surgery;Neurovascular bundle (NVB) preservation status and erectile function preservation rate;Rate of surgical plan modification (change in surgical approach);

Countries

China

Contacts

Public ContactBangmin Han

Shanghai General Hospital

hanbm@163.com+86 189 3975 7031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026